Table 3 Effect on event-free survival by... | American Society of Hematology

Table 3

Effect on event-free survival by univariate and multivariate analysis

Factors/variables*	Effect	Univariate P	Multivariate P, coefficient
Age	NS
Months on imatinib 400 mg	Better	.02	NS
CML duration	Worse	.01	NS
Previous major cytogenetic response	Better	.003	NS
Higher hemoglobin	NS
Higher platelets count	NS
Leukocytosis	Worse	< .001	< .001, .049
Higher pb basophils %	Worse	.02	NS
Higher pb blasts %	Worse	< .001	NS
Higher marrow basophils %	Worse	.05	NS
Higher marrow blasts %	Worse	< .001	< .001, .317
Clonal evolution	Worse	.01	NS
Higher Philadelphia-metaphases %	Worse	< .001	< .001, .021
400 mg failure (vs hematologic failure)
Cytogenetic resistance	Better	.001	NS
Cytogenetic relapse	Better	.001	NS
Mutation versus no mutation	NS
Dose reduction	Better	.01	NS
Achievement of MCyR after dose escalation†	Better	.03	NS

Factors/variables*	Effect	Univariate P	Multivariate P, coefficient
Age	NS
Months on imatinib 400 mg	Better	.02	NS
CML duration	Worse	.01	NS
Previous major cytogenetic response	Better	.003	NS
Higher hemoglobin	NS
Higher platelets count	NS
Leukocytosis	Worse	< .001	< .001, .049
Higher pb basophils %	Worse	.02	NS
Higher pb blasts %	Worse	< .001	NS
Higher marrow basophils %	Worse	.05	NS
Higher marrow blasts %	Worse	< .001	< .001, .317
Clonal evolution	Worse	.01	NS
Higher Philadelphia-metaphases %	Worse	< .001	< .001, .021
400 mg failure (vs hematologic failure)
Cytogenetic resistance	Better	.001	NS
Cytogenetic relapse	Better	.001	NS
Mutation versus no mutation	NS
Dose reduction	Better	.01	NS
Achievement of MCyR after dose escalation†	Better	.03	NS

CML indicates chronic myeloid leukemia; pb, peripheral blood; MCyR, major cytogenetic response; and NS, not significant.

Values were obtained at the time of 400 mg failure.

Time-dependent variable.